Abstract
Objective
Materials and Methods
Results
Conclusion
Purchase one-time access:
Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online accessOne-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
Subscribe:
Subscribe to UrologyReferences
- Male reproductive disorders and fertility trends: influences of environment and genetic susceptibility.Physiol Rev. 2016; 96: 55-97
- Regional differences in semen quality in Europe.Hum Reprod. 2001; 16: 1012-1019
- Geographic differences in semen quality of fertile U.S. males.Environ Health Perspect. 2003; 111: 414-420
- Body mass index in relation to semen quality and reproductive hormones in New Zealand men: a cross-sectional study in fertility clinics.Hum Reprod. 2013; 28: 3178-3187
- Cigarette smoking and semen quality: a new meta-analysis examining the effect of the 2010 world health organization laboratory methods for the examination of human semen.Eur Urol. 2016; 70: 635-645
- Semen quality of young men from the general population in Baltic countries.Hum Reprod. 2017; 32: 1334-1340
- Semen parameters in fertile US men: the study for future families.Andrology. 2013; 1: 806-814
- Racial variation in semen quality at fertility evaluation.Urology. 2017; 106: 96-102
- Male infertility and risk of nonmalignant chronic diseases: a systematic review of the epidemiological evidence.Semin Reprod Med. 2017; 35: 282-290
- Optum labs: building a novel node in the learning health care system.Health Aff (Millwood). 2014; 33: 1187-1194
- World Health Organization reference values for human semen characteristics.Hum Reprod Update. 2010; 16: 231-245
- Semen quality among Danish and Finnish men attempting to conceive. The Danish First Pregnancy Planner Study Team.Eur J Endocrinol. 2000; 142: 47-52
- East-West gradient in semen quality in the Nordic-Baltic area: a study of men from the general population in Denmark, Norway, Estonia and Finland.Hum Reprod. 2002; 17: 2199-2208
- Semen analyses in 1,283 men from the United States over a 25-year period: no decline in quality.Fertil Steril. 1996; 65: 1009-1014
- Semen quality in relation to biomarkers of pesticide exposure.Environ Health Perspect. 2003; 111: 1478-1484
- Role of genetics in azoospermia.Urology. 2011; 77: 598-601
- Semen quality of fertile Japanese men: a cross-sectional population-based study of 792 men.BMJ Open. 2013; 3
- Reference values for vertebral shape in young Chinese women: implication for assessment of vertebral deformity.Eur Spine J. 2010; 19: 1162-1168
- The use of genomics, proteomics, and metabolomics in identifying biomarkers of male infertility.Fertil Steril. 2013; 99: 998-1007
- Impact of CAG repeat length in the androgen receptor gene on male infertility—a meta-analysis.Reprod Biomed Online. 2016; 33: 39-49
- Socioeconomic and racial disparities among infertility patients seeking care.Fertil Steril. 2006; 85: 876-881
- Infertility services reported by men in the United States: national survey data.Fertil Steril. 2009; 91: 2466-2470
- Consistent age-dependent declines in human semen quality: a systematic review and meta-analysis.Ageing Res Rev. 2015; 19: 22-33
- The age of fathers in the USA is rising: an analysis of 168 867 480 births from 1972 to 2015.Hum Reprod. 2017; 32: 2110-2116
- Parental age and risk of pediatric cancer in the offspring: a population-based record-linkage study in California.Am J Epidemiol. 2017; 186: 843-856
- Maternal and paternal age and risk of autism spectrum disorders.Arch Pediatr Adolesc Med. 2007; 161: 334-340
- Risk of diabetes according to male factor infertility: a register-based cohort study.Hum Reprod. 2017; 32: 1-8
- Prevalences of oligozoospermia and azoospermia in male partners of infertile couples from different parts of India.Asian J Androl. 2006; 8: 89-93
- The epidemiology and etiology of azoospermia.Clinics (Sao Paulo). 2013; 68: 15-26
- Lifestyle factors and reproductive health: taking control of your fertility.Reprod Biol Endocrinol. 2013; 11: 66
Article info
Publication history
Footnotes
Financial Disclosure: CHG, SL, CAZ, and JPB declare no support from any organization for the submitted work; no financial relationships with any organizations that might have an interest in the submitted work in the previous 3 years; no other relationships or activities that could appear to have influenced the submitted work. ME is an advisor for Sandstone. AG reports personal fees from Merck-Serono, Finox, IBSA Pharmaceuticals, Ferring Pharmaceuticals, and from Novo-Nordisk, outside the submitted work.
Funding Support: The ReproUnion collaborative study, co-financed by the European Union, Interreg VÖKS paid a portion of CHG's salary and expenses.